Compare AU
Compare RSSL vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RSSL and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
RSSL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 76 |
Median incremental investment | $2,016.86 | $651.42 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $1,428.99 | $1,249.80 |
Average age group | > 35 | > 35 |
Key Summary
RSSL | CURE | |
|---|---|---|
Strategy | RSSL.AX was created on 2025-02-10 by Global X. The fund's investment portfolio concentrates primarily on small cap equity. The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the Russell 2000 RIC Capped Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Global X Russell 2000 ETF (100 %) | Exact Sciences Corp (3.25 %) Alnylam Pharmaceuticals Inc (3.03 %) Neurocrine Biosciences Inc (2.99 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0 % | 0.45 % |
Key Summary
RSSL | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Russell 2000 RIC Capped Index - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $8.74 | $41.66 |
Size | $3.879 million | $30.087 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 4.24 % |
Market | ASX | ASX |
First listed date | 11/02/2025 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RSSL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 76 |
Median incremental investment | $2,016.86 | $651.42 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $1,428.99 | $1,249.80 |
Average age group | > 35 | > 35 |
Pros and Cons
RSSL | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RSSL | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |